论文部分内容阅读
为探讨可溶性白细胞介素－６受体（ｓＩＬ－６Ｒ）在多发性硬化（ＭＳ）发生、发展中的作用，采用双抗体夹心ＥＬＩＳＡ方法，对２８例ＭＳ患者和２５例正常对照组血清ｓＩＬ－６Ｒ水平进行了测定。结果显示缓解－复发型和进展型ＭＳ患者血清ｓＩＬ－６Ｒ水平明显高于正常对照组和良性型组（Ｐ＜０．０５，Ｐ＜０．０１）；而良性型ＭＳ患者血清ｓＩＬ－６Ｒ水平与正常对照组相比，未见明显改变。缓解－复发型ＭＳ患者血清ｓＩＬ－６Ｒ水平随着病情的好转而下降。ｓＩＬ－６Ｒ水平与ＭＳ患者头颅ＭＲＩ上的病灶大小和部位无明显相关性（ｒ１＝０．１２４，Ｐ＞０．０５；ｒ２＝０．０９１，Ｐ＞０．０５）。推测ｓＩＬ－６Ｒ水平的高低可作为判断ＭＳ患者病情变化的指标之一。
To investigate the role of soluble interleukin-6 receptor (sIL-6R) in the occurrence and development of multiple sclerosis (MS), the serum sIL-6R levels in 28 patients with MS and 25 normal controls were measured by double antibody sandwich ELISA. 6R levels were measured. The results showed that serum sIL-6R levels in patients with remission and progressive MS were significantly higher than those in normal control group and benign group (P <0.05, P <0.01), while serum sIL-6R levels Compared with the normal control group, no significant changes were observed. The level of sIL-6R in remission-relapsing MS patients decreased with the improvement of the disease. There was no significant correlation between the level of sIL-6R and the size and location of the lesion on MRI (r1 = 0.124, P> 0.05; r2 = 0.091, P> 0.05). Speculated that the level of sIL-6R levels can be used as one of the indicators to determine the severity of MS patients.